NewsPronto

 
Men's Weekly

.

ACN Newswire

Read more press releases from ACN Newswire here

Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea

  • Written by ACN Newswire

image

TOKYO, Sep 30, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Seikagaku Corporation announced today that the companies have entered into an agreement for the marketing alliance in South Korea for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. Eisai and Seikagaku signed an agreement...

Read more: Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of...